The global transition toward clean-energy technologies, advanced electronics, and electric mobility relies heavily on an uninterrupted supply of critical minerals…
Read More
Tufts model estimates 82x ROI and up to $21 million in value from Medable AI agent
The integration of artificial intelligence into the pharmaceutical industry has reached a critical inflection point, as a new collaborative analysis…
Read More
BeOne Medicines Invests $300 Million to Expand Hopewell, New Jersey Manufacturing and Research Operations, Pushing Total US Investment Past $1 Billion
BeOne Medicines is significantly bolstering its presence in the United States with a substantial $300 million investment earmarked for the…
Read More
Ipsen Acquires Rare Disease Specialist Memo Therapeutics for up to €700 Million, Bolstering Pipeline with Promising BK Polyomavirus Asset
Paris, France – In a significant strategic move to expand its rare disease portfolio, global biopharmaceutical company Ipsen announced today…
Read More
Absci Secures $100 Million and Advances AI-Designed Drug Candidate ABS-201 for Endometriosis and Hair Loss
Absci Corporation has successfully closed an underwritten public offering, raising approximately $100 million, a significant financial injection that will fuel…
Read More
The Enduring Secrets of Ancient Bone: New Study Reveals Preserved Collagen in 66-Million-Year-Old Dinosaur Fossil
For decades, the scientific consensus held that dinosaur fossils were essentially mineralized relics, their original organic components irrevocably lost to…
Read More
Vedana Therapeutics Secures $46 Million Series A to Advance Next-Generation Migraine Prevention Therapies Targeting PACAP
Seattle-based biotech firm Vedana Therapeutics has successfully closed a $46 million Series A financing round, a significant infusion of capital…
Read More
Parabilis Medicines Aims for $475 Million Nasdaq IPO to Advance Lead Cancer Asset Zolucatetide
Parabilis Medicines, a promising biotechnology firm, is strategically positioning itself for a significant public market debut, announcing its intention to…
Read More
Parabilis Medicines Aims for $475 Million Nasdaq IPO to Fund Pivotal Desmoid Tumour Trial and Pipeline Expansion
Parabilis Medicines, a biopharmaceutical company forging innovative therapeutic pathways, is charting a course for public market debut with a proposed…
Read More
Contraline Secures $92.5 Million in Series B Funding to Advance Reversible Male Contraceptive to Late-Stage Clinical Trials
Contraline, a pioneering biotechnology firm backed by Google Ventures, has successfully closed a substantial $92.5 million Series B financing round.…
Read More
